Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:AZN)

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

Business Wire 7 days ago

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Business Wire 12 days ago

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Business Wire April 5, 2024

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Business Wire April 5, 2024

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Business Wire April 5, 2024

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Business Wire April 2, 2024

VOYDEYA(TM) approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Business Wire April 1, 2024

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Business Wire March 25, 2024

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Business Wire March 19, 2024
View More News ››

Opinion & Analysis (NDAQ:AZN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:AZN)

Datopotamab Deruxtecan Biologics License Application Accepte

Just In: $AZN Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced...
whytestocks - February 19, 2024

AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

Breaking News: $AZN AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript2024-02-08 16:15:30 ET Image source: The Motley Fool...
whytestocks - February 8, 2024

Hospital Infection Therapeutics Market Size & Share 2021-26

According to IMARC Group’s latest report, titled “Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth...
edwardebreen15 - August 22, 2022

Aztra vaccine coming to Canada soon news?

https://www.msn.com/en-ca/news/newspolitics/health-canada-to-decide-on-astrazeneca-covid-19-vaccine-in-coming-days/ar-BB1ddoDT?ocid...
Rejean1 - January 29, 2021

Conflicting news???

I thought I just read elsewhere they had banned shots to people over 65? A month after it received approval in the UK, the EU’s...
Rejean1 - January 29, 2021

5 dead in Astrazeneca fire in India.

https://www.bbc.com/news/world-asia-india-55753586
Rejean1 - January 21, 2021
View more Bullboard ››

Star Diamond Corp

Star Diamond Corp

Star Diamond Corporation is a Canada-based company engaged in the acquisition, exploration and development of mineral ...
View More »